Reviewing CryoPort (NASDAQ:CYRX) & Illumina (NASDAQ:ILMN)

CryoPort (NASDAQ:CYRX) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares CryoPort and Illumina’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Illumina	18.36%	29.84%	12.17%

Institutional & Insider Ownership

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 9.5% of CryoPort shares are owned by company insiders. Comparatively, 2.9% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares CryoPort and Illumina”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18 million	4.43	$78.30 million	$1.35	11.47
Illumina	$4.34 billion	6.90	$850.00 million	$5.36	36.97

Illumina has higher revenue and earnings than CryoPort. CryoPort is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for CryoPort and Illumina, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0	2	7	0	2.78
Illumina	2	6	8	0	2.38

CryoPort presently has a consensus target price of $16.38, suggesting a potential upside of 5.71%. Illumina has a consensus target price of $188.40, suggesting a potential downside of 4.93%. Given CryoPort’s stronger consensus rating and higher possible upside, research analysts plainly believe CryoPort is more favorable than Illumina.

Volatility and Risk

CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Summary

Illumina beats CryoPort on 8 of the 14 factors compared between the two stocks.

About CryoPort

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

About Illumina

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.